A First-in-human Study to Assess OT-C001 (Amplified/Activated Allogenic Natural Killer Cells) in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma

Inclusion Criteria: * ≥18 years of age * histologically confirmed diagnosis of R/R DLBCL-NOS without further standard treatment options including those relapsing after or ineligible for CAR T-cell therapy * with evaluable disease * with adequate biological parameters at baseline * ECOG performance status ≤1 * life expectancy \>3 months as assessed by the investigator Exclusion Criteria: * Receive concomitantly any antitumor-directed drug therapy * Any vaccination with live virus vaccines before or during treatment * With severe atopic predisposition who need a treatment with monoclonal antibodies, allergen immunotherapy, or long-term systemic corticosteroids * Major surgery within 3 weeks * With rapidly progressing disease that includes massive uncontrolled pleural, pericardial, or peritoneal effusions, pulmonary lymphangitis, and over 50% liver involvement * Ongoing immune-related tocivities or adverse events grade \>1 not resolved from previous therapies except vitiligo, stable neuropathy up to grade 2, hair loss, and stable endocrinopathies with substitutive hormone therapy * Documented history of active autoimmune disorders requiring systemic immunosuppressive therapy within the last 12 months * Primary or secondary immune deficiency * Active and uncontrolled infections requiring intravenous antibiotic or antiviral treatment * Seropositive (except after vaccination or confirmed cure for hepatitis) for HIV, HBV, or HCV * Clinically significant cardiac disease including heart failure, uncontrolled hypertension, pre-existing arrhythmia, uncontrolled angina pectoris, or myocardial infarction within 12 months * Dementia or altered mental status that would prohibit informed consent * Other malignancy within the last 3 years except adequately treated nonmelanoma skin cancer, in situ carcinoma of the uterine cervix, or myelodysplastic syndromes